title: Lemierre's syndrome with double heterozygote status in the methylenetetrahydrofolate reductase gene.
abstract: BACKGROUND
  There are some risk factors being more vulnerable to Lemierre's syndrome such as a hypercoagulable state.
  
  
  METHODS
  We report a rare case of Lemierre's syndrome with ethmoid and maxillary sinusitis, bilateral mastoiditis, and sigmoid sinus thrombosis.
  
  
  RESULTS
  Genetic study revealed a double heterozygote status in the methylenetetrahydrofolate reductase gene including C677T and A1298C.
  
  
  CONCLUSIONS
  It is suggested to screen patients with Lemierre's syndrome for a hypercoagulable state to consider anticoagulant therapy.
authors.affiliation: Pediatric Infectious Diseases, Department of Pediatrics, Najmieh Hospital, Baghyatollah University of Medical Sciences, Tehran, Iran.
authors.forename: Mostafa
authors.initials: M
authors.lastname: Behpour-Oskooee
authors.forename: Abdollah
authors.initials: A
authors.lastname: Karimi
authors.forename: Shirin
authors.initials: S
authors.lastname: Sayyahfar
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002443:Ceftriaxone / Q000627:therapeutic use; D002648:Child; D002981:Clindamycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006579:Heterozygote; D006801:Humans; D057831:Lemierre Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D015415:Biomarkers; D006495:Heparin, Low-Molecular-Weight; D002981:Clindamycin; D002443:Ceftriaxone; D042965:Methylenetetrahydrofolate Reductase (NADPH2)